Medically Minded, Inc. (OTC Pink: MMHC) to Launch New Product Line

ST. THOMAS, U.S. VIRGIN ISLANDS--(Marketwired - Mar 16, 2016) -  Medically Minded, Inc. (OTC PINK: MMHC), announced that it will begin marketing and distributing end consumer products containing the hemp plant extract or Cannabidiol ("CBD") under the "Medically Minded" brand name. These products will include 100% CBD-Rich Hemp Oil in a variety of sizes and flavors.

CBD Rich Hemp Oil is an oil extracted from Industrial Hemp plants (stalks and seeds) with a High Grade of Cannabidiol (CBD). The plants used are specifically and uniquely bred to comprise high concentrations of the naturally occurring Cannabinoid Cannabidiol (CBD). Cannabidiol oil that comes from industrial hemp plants, such as will be the case with our products, are considered by the FDA to be a dietary supplement (not a medication) since they are made from industrial hemp plants.

If you live in the US, this means you don't need a prescription and can legally purchase and consume Cannabidiol in any state. Cannabidiol from industrial hemp also has the added benefit of having virtually no THC. This is why it's not possible to get "high" with these products. There simply isn't enough THC.

The Company is currently completing initial discussions with a manufacturer and supplier of quality, high-grade CBD rich hemp oil to supply the products for our initial territorial launches. The Company expects to announce an initial Memorandum of Understanding for a supplier/distribution relationship shortly.

Stephen Jones, CEO of Medically Minded, stated, "While we continue our push for a medical marijuana space in the U.S. Virgin Islands, we felt it was important to expand into other areas of the Cannabidiol industry that could provide beneficial products to the market and immediate revenues to the Company and its shareholders."

Jones continued, "After extensive research into the industrial hemp-CBD market, we concluded that there is a growing demand and need for CBD-enriched products. Current studies have also shown an interest and basis for further trials for CBD in the areas of pain, epilepsy, and brain diseases to name a few."

Medically Minded is excited about the opportunity to enter the revenue generating phase with the launch of its "Medically Minded" brand of CBD-enriched products. In an effort to move forward immediately with its business plan, management has been exploring a potential relationship with an experienced manufacturer to provide the initial product line, developing a variety of product marketing campaigns, and identifying support among several key investors.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.

SAFE HARBOR AND INFORMATIONAL STATEMENT: This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may", "would", "will", "expect", "estimate", "anticipate", "believe", "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the Company's reports filed with the SEC. The Company is not eligible to rely on the safe harbor provided by Section 21E(c) of the Exchange Act because it is not subject to filing periodic reports under Sections 13 or 15(d) of the Exchange Act.